ArticleThe oncologist2025
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events.
Kazuyuki Mizuno et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this paperpooled ittrialcites it